Liquidia Co. (NASDAQ:LQDA) is expected to post earnings of -$0.20 per share
Wall Street brokers expect Liquidia Co. (NASDAQ:LQDA – Get Rating) to report ($0.20) earnings per share for the current fiscal quarter, according to Zacks. Three analysts provided Liquidia earnings estimates, with estimates ranging from ($0.22) to ($0.18). Liquidia reported earnings of ($0.21) per share in the same quarter last year, indicating a positive year-over-year growth rate of 4.8%. The company is due to release its next quarterly earnings report on Monday, January 1.
According to Zacks, analysts expect Liquidia to report full year earnings of ($0.86) per share for the current year, with EPS estimates ranging from ($0.94) to ($0. $72). For next year, analysts expect the company to report earnings of ($0.44) per share, with EPS estimates ranging from ($1.05) to $0.14. Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts who cover Liquidia.
Liquidia (NASDAQ:LQDA – Get Rating) last released its results on Thursday, March 17. The company reported ($0.23) EPS for the quarter, missing Thomson Reuters consensus estimate of ($0.11) by ($0.12). The company posted revenue of $3.22 million in the quarter, versus analyst estimates of $2.89 million. In the same quarter last year, the company made ($0.38) earnings per share.
Several research analysts have weighed in on the company recently. Needham & Company LLC raised its price target on Liquidia from $8.00 to $12.00 and gave the stock a “buy” rating in a Monday, Jan. 10 research note. HC Wainwright raised its price target on Liquidia from $6.00 to $16.00 and gave the stock a “buy” rating in a Thursday, Feb. 3 research note. Wedbush reaffirmed a “hold” rating and posted a $6.00 price target on Liquidia shares in a research note on Friday, January 7. Finally, Zacks Investment Research upgraded Liquidia from a “hold” rating to a “sell” rating in a Wednesday, April 6 research note.
Liquidia stock traded down $0.09 by midday on Friday, hitting $5.63. The company had a trading volume of 658,038 shares, compared to its average volume of 653,730. The stock’s 50-day moving average price is $6.44 and its two-hundred-day moving average price is of $5.26. Liquidia has a 12-month low of $2.25 and a 12-month high of $7.78. The company has a market capitalization of $362.26 million, a PE ratio of -7.93 and a beta of 0.13.
In other news, Director Caligan Partners Lp acquired 1,764,705 Liquidia shares in a transaction that took place on Monday, April 18. The stock was purchased at an average price of $5.10 per share, for a total transaction of $8,999,995.50. Following completion of the transaction, the administrator now owns 10,093,123 shares of the company, valued at $51,474,927.30. The purchase was disclosed in a filing with the Securities & Exchange Commission, available on the SEC’s website. 29.50% of the shares are currently held by company insiders.
Institutional investors have recently been buying and selling shares of the stock. UBS Group AG increased its position in Liquidia by 205.4% in the third quarter. UBS Group AG now owns 10,151 shares of the company worth $28,000 after purchasing an additional 6,827 shares last quarter. Marshall Wace LLP purchased a new stake in Liquidia in the first quarter worth approximately $32,000. Qube Research & Technologies Ltd acquired a new stake in Liquidia in the fourth quarter worth approximately $55,000. BNP Paribas Arbitrage SA increased its position in Liquidia by 4,365.4% in the fourth quarter. BNP Paribas Arbitrage SA now owns 12,771 shares in the company worth $62,000 after buying an additional 12,485 shares last quarter. Finally, Schonfeld Strategic Advisors LLC increased its position in Liquidia by 17.2% in the third quarter. Schonfeld Strategic Advisors LLC now owns 25,200 shares of the company worth $69,000 after buying 3,700 additional shares in the last quarter. Institutional investors hold 33.61% of the company’s shares.
About Liquidia (Get a rating)
Liquidia Corporation, a biopharmaceutical company, develops, manufactures and markets various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension.
Get a Free Copy of Zacks Research Report on Liquidia (LQDA)
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
Receive news and reviews for Liquidia Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst notes for Liquidia and related companies with MarketBeat.com’s free daily email newsletter.